Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
MLYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.24 - $18.38
Previous CloseN/A
Volume137.34K
Average Volume (3M)715.63K
Market Cap
$847.28M
Enterprise Value$501.21M
Total Cash (Recent Filing)$343.03M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 12, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding65,175,285
10 Day Avg. Volume673,542
30 Day Avg. Volume715,626
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.69K
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$36.86Price Target Upside183.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMineralys has already presented positive data with lorundrostat across two pivotal studies in uncontrolled/resistant hypertension.
Market PotentialThe size of the market is significant, with a projection of over $5 billion as a large percentage of hypertensive patients do not have their systolic blood pressure under control.
Bears Say
CompetitionCompetitor AZN could launch around the same time with more marketing and commercial presence.
Investor SentimentShort interest for Mineralys is relatively high, indicating a potential bearish sentiment among some investors.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $18.38 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $847.28M.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2025 which is tomorrow.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 12, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.982 by $0.192.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.74.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 65,175,285 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.982. Following the earnings report the stock price went up 1.199%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.86 (183.54% Upside)
$36.86 (183.54% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.38%
12-Months-Change
Fundamentals
Return on Equity
-56.31%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing innovative therapies for the treatment of cardiovascular and renal diseases. The company operates within the healthcare sector and specializes in the research and development of novel therapeutic solutions aimed at addressing unmet medical needs in these areas. Mineralys’ core product pipeline is centered around the development of targeted treatments that leverage its expertise in mineralocorticoid receptor biology.
MLYS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and financial achievements, including successful trial results for lorundrostat, high physician interest, and strong financial backing. However, challenges remain, such as increased net loss and manageable concerns regarding hyperkalemia. Overall, the positive developments outweigh the challenges.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$36.86
▲(183.54% Upside)
Technical Analysis
Ownership Overview
42.32% Insiders
7.79% Mutual Funds
0.59% Other Institutional Investors
38.96% Public Companies and
Individual Investors